Axsome Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Axsome Therapeutics has a total shareholder equity of $92.9M and total debt of $180.0M, which brings its debt-to-equity ratio to 193.8%. Its total assets and total liabilities are $561.5M and $468.6M respectively.
Key information
193.8%
Debt to equity ratio
US$180.00m
Debt
| Interest coverage ratio | n/a |
| Cash | US$327.34m |
| Equity | US$92.90m |
| Total liabilities | US$468.56m |
| Total assets | US$561.46m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 19X's short term assets ($479.1M) exceed its short term liabilities ($196.2M).
Long Term Liabilities: 19X's short term assets ($479.1M) exceed its long term liabilities ($272.4M).
Debt to Equity History and Analysis
Debt Level: 19X has more cash than its total debt.
Reducing Debt: 19X's debt to equity ratio has reduced from 289.6% to 193.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 19X has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 19X has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.